T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions

Tumor, Solid

Interventions

DRUG

NW-301V

TCR-T cell targeting KRAS G12V mutation

DRUG

NW-301D

TCR-T cell targeting KRAS G12D mutation

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou